<DOC>
	<DOCNO>NCT00015873</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . It yet know combination chemotherapy regimen effective treat infant acute lymphoblastic leukemia . PURPOSE : Randomized phase III trial compare effectiveness different combination chemotherapy regimens treat infant newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Comparison Different Combination Chemotherapy Regimens Treating Infants With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine outcome induction chemotherapy follow consolidation reinduction chemotherapy without late intensification chemotherapy follow maintenance regimen allogeneic bone marrow transplantation infant newly diagnose acute lymphoblastic leukemia . - Determine value late intensification course reinduction maintenance therapy patient . - Determine prognostic value age , immunophenotype , WBC , day 15 bone marrow status , MLL gene rearrangement patient treat regimen . OUTLINE : This partially randomize , multicenter study . Patients stratify accord risk ( high vs standard ) . Patients receive induction therapy comprise prednisone orally IV three time day day 1-7 ; dexamethasone orally IV three time day day 8-35 ; vincristine IV day 8 , 16 , 22 , 30 ; cytarabine IV 30 minute day 8-21 ; daunorubicin IV 60 minute day 8 9 ; asparaginase IV 1 hour intramuscularly ( IM ) day 15 , 18 , 22 , 25 , 29 , 33 ; methotrexate intrathecally ( IT ) day 1 29 ; cytarabine IT day 15 . Patients receive prednisolone IT combination dose intrathecal chemotherapy . Patients CNS involvement receive additional dos methotrexate IT day 8 22 weekly day 29 evidence CNS leukemia . After achieve complete remission , patient receive MARAM chemotherapy comprise oral mercaptopurine daily day 1-14 ; methotrexate IV 24 hour day 1 8 ; leucovorin calcium orally IV 36 , 42 , 48 hour begin dose oral methotrexate ; methotrexate IT day 2 9 ; cytarabine IV 3 hour twice daily day 15 , 16 , 22 , 23 ; asparaginase IV 1 hour IM day 16 23 . Patients receive prednisolone IT combination dose intrathecal methotrexate . At least 2 week completion MARAM chemotherapy , patient receive OCTADD chemotherapy comprise oral dexamethasone three time day day 1-21 ; oral thioguanine daily day 1-28 36-49 ; vincristine IV day 2 , 8 , 16 , 22 ; daunorubicin IV 60 minute day 1 , 8 , 15 , 22 ; cytarabine IV day 2-5 , 9-12 , 16-19 , 23-26 , 37-40 , 45-48 ; cytarabine IT day 1 15 ; cyclophosphamide IV 1 hour day 36 49 . Patients receive prednisolone IT combination dose intrathecal methotrexate . Patients randomize one two treatment arm late intensification therapy . - Arm I : Beginning least 1 week completion OCTADD chemotherapy , patient receive VIMARAM chemotherapy comprise vincristine IV day 1 , 8 , 15 , 22 ; oral mercaptopurine daily day 1-14 ; methotrexate IV 24 hour day 1 8 ; leucovorin calcium orally IV 36 , 42 , 48 hour begin dose oral methotrexate ; methotrexate IT day 2 9 ; cytarabine IV 3 hour twice daily day 15 , 16 , 22 , 23 ; asparaginase IV 1 hour IM day 16 23 . Patients receive prednisolone IT combination dose intrathecal methotrexate . Patients receive appropriate maintenance therapy . - Arm II : Patients receive VIMARAM chemotherapy receive appropriate maintenance therapy . At least 2 week completion last course chemotherapy , patient receive maintenance therapy . Patients good response initial therapy prednisone receive maintenance therapy comprise oral dexamethasone three time daily week 1 2 ; vincristine IV day 2 week 1 2 ; oral mercaptopurine daily week 1-14 ; oral methotrexate weekly week 1-14 . Patients poor response initial therapy prednisone receive maintenance therapy comprise oral mercaptopurine daily week 1-14 ; oral methotrexate weekly week 1-14 ; oral dexamethasone three time daily week 1 2 ; vincristine IV day 2 week 1 2 ; etoposide IV 2 hour weekly week 8 9 ; cytarabine IV 1 hour weekly week 8 9 . Treatment repeat maintenance therapy regimens every 14 week total 3 course . Patients also receive methotrexate IT day 1 first third course therapy cytarabine IT day 1 second course therapy . Patients receive prednisolone IT combination dose intrathecal chemotherapy . Beginning completion maintenance therapy , patient receive continue maintenance therapy comprise oral mercaptopurine daily oral methotrexate week . Treatment continue 104 week initial diagnosis . Patients poor response initial therapy prednisone may receive allogeneic bone marrow transplantation donor available . The patient undergoes transplantation immediately OCTADD chemotherapy rather randomize receive maintenance therapy . These patient receive condition regimen comprise oral busulfan four time day day -8 -5 , etoposide IV 4 hour day -4 , methotrexate IT day -3 , cyclophosphamide IV 1 hour day -3 -2 . Allogenic bone marrow transplant day 0 . Patients receive cyclosporine orally IV day 1-180 graft-versus-host disease prophylaxis . Patients follow annually . PROJECTED ACCRUAL : A total 350 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute lymphoblastic leukemia ( ALL ) Newly diagnose Morphological verification cytochemistry immunophenotyping CNS testicular leukemia diagnosis allow Trisomy 21 allow PATIENT CHARACTERISTICS : Age : 365 day less Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy leukemia Endocrine therapy : At least 4 week since prior systemic corticosteroid Prior inhale steroid allow Radiotherapy : No prior radiotherapy leukemia Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
</DOC>